Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > buck passed

<< Previous

Bullboard Posts

Next >>

Comment by Buckhenryon Sep 06, 2022 4:15pm

183 Views

Post# 34944865

RE:RE:RE:RE:RE:buck passed

I'm all onboard or would not own many many shares. many like me are tired of just talk and no interest in this stock over the last 4 years. oncy leadership has done a horrible job in investor relations

<< Previous

Bullboard Posts

Next >>

This AI stock is disrupting the event tickets monopoly